Exchange transfusions
Much like with phototherapy the level at which exchange transfusion should occur depends on the health status and age of the newborn. It should however be used for any newborn with a total serum bilirubin of greater than 428 μmol/L ( 25 mg/dL ). : 2533

Research
Penicillamine was studied in the 1970s in hyperbilirubinemia due to ABO hemolytic disease. While tin mesoporphyrin IX may decrease bilirubin such use is not recommended in babies. Preclinical studies have looked at minocycline to help prevent neurotoxicity. Clofibrate may decrease the duration of phototherapy. Evidence as of 2012 however is insufficient to recommend its use. References
External links
American Academy of Pediatrics has issued guidelines for managing this disease, which can be obtained for free. National Institute for Health and Care Excellence (NICE) has issued guidelines for the recognition and treatment of neonatal jaundice in the United Kingdom.
Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010, the US rights were sold to Warner Chilcott for US$400 million. Adverse effects
Darifenacin should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment. Medical uses
Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults. It may also be recommended with an alpha blocker to help provide symptomatic benefit for overactive bladder and obstructive symptoms such as likely associated with benign prostatic hypertrophy. Mechanism of action
Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome. References
External links
"Darifenacin". Drug Information Portal. U.S. National Library of Medicine. "Darifenacin hydrobromide". Drug Information Portal. U.S. National Library of Medicine.